(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199451 A8

(51) International Patent Classification:
A61K 35/28 (2015.01) *A61P 25/28* (2006.01)
A61K 35/30 (2015.01) *G01N 33/68* (2006.01)

(21) International Application Number:
PCT/US2025/020930

(22) International Filing Date:
21 March 2025 (21.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/568,286	21 March 2024 (21.03.2024)	US
63/702,937	03 October 2024 (03.10.2024)	US
63/703,501	04 October 2024 (04.10.2024)	US

(71) Applicant: **LONGEVERON INC.** [US/US]; 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136 (US).

(72) Inventors: **HARE, Joshua M.**; 201 Aqua Ave, Apt 1003, Miami Beach, Pennsylvania 33141 (US). **RASH, Brian G.**; c/o Longeveron Inc., 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136 (US).

(74) Agent: **POINTON, Kathleen M.**; Buchanan Ingersoll & Rooney, 501 Grant St Suite 200, Pittsburgh, Pennsylvania 15219 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHOD OF TREATMENT OF ALZHEIMER'S DISEASE WITH MESENCHYMAL STEM CELLS AND MMP-14 POTENCY ASSAY FOR MESENCHYMAL STEM CELLS



FIG. 1

(57) Abstract: Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.

[Continued on next page]

WO 2025/199451 A8

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) **Date of publication of the international search report:**
27 November 2025 (27.11.2025)

(48) **Date of publication of this corrected version:**
05 February 2026 (05.02.2026)

(15) **Information about Correction:**
see Notice of 05 February 2026 (05.02.2026)